{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:53:41Z","timestamp":1791993221095,"version":"4.4.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"am","delay-in-days":350,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.ijcard.2021.08.031","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T22:58:56Z","timestamp":1629845936000},"page":"96-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH) registry"],"prefix":"10.1016","volume":"340","author":[{"given":"Fabien","family":"Picard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9gory","family":"Ducrocq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Magnus","family":"Ohman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A.","family":"Eagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.F.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Sidney C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yedid","family":"Elbez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2021.08.031_bb0005","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.ijcard.2021.08.031_bb0010","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2021.08.031_bb0015","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","article-title":"Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial","volume":"51","author":"Miller","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2021.08.031_bb0020","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.amjcard.2009.04.008","article-title":"Plasma triglycerides and cardiovascular events in the treating to new targets and incremental decrease in end-points through aggressive lipid lowering trials of statins in patients with coronary artery disease","volume":"104","author":"Faergeman","year":"2009","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2021.08.031_bb0025","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/j.jacc.2015.03.544","article-title":"Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins","volume":"65","author":"Schwartz","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2021.08.031_bb0030","doi-asserted-by":"crossref","first-page":"27-10","DOI":"10.1007\/s11883-021-00919-2","article-title":"Cardiovascular disease risk reduction in mild-moderate hypertriglyceridemia: integrating prescription of Omega-3 with standard treatment","volume":"23","author":"Picard","year":"2021","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.ijcard.2021.08.031_bb0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2021.08.031_bb0040","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.jacc.2019.02.032","article-title":"Effects of icosapent ethyl on Total ischemic events: from REDUCE-IT","volume":"73","author":"Bhatt","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2021.08.031_bb0045","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jacl.2019.10.014","article-title":"National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk","volume":"13","author":"Orringer","year":"2019","journal-title":"J. Clin. Lipidol."},{"issue":"2020","key":"10.1016\/j.ijcard.2021.08.031_bb0050","first-page":"111","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2021.08.031_bb0055","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/archinte.167.1.68","article-title":"External validity of clinical trials in acute myocardial infarction","volume":"167","author":"Steg","year":"2007","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ijcard.2021.08.031_bb0060","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jacc.2019.01.016","article-title":"Generalizability of the REDUCE-IT trial in patients with stable coronary artery disease","volume":"73","author":"Picard","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2021.08.031_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2005.11.004","article-title":"The REduction of atherothrombosis for continued health (REACH) registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design","volume":"151","author":"Ohman","year":"2006","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2021.08.031_bb0070","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/jama.295.2.180","article-title":"International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis","volume":"295","author":"Bhatt","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2021.08.031_bb0075","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jama.297.11.1197","article-title":"One-year cardiovascular event rates in outpatients with atherothrombosis","volume":"297","author":"Steg","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2021.08.031_bb0080","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/jama.2010.1322","article-title":"Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis","volume":"304","author":"Bhatt","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2021.08.031_bb0085","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1093\/eurheartj\/ehx658","article-title":"External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry","volume":"39","author":"Darmon","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2021.08.031_bb0090","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/clc.22692","article-title":"Rationale and design of REDUCE-IT: reduction of cardiovascular events with icosapent ethyl-intervention trial","volume":"40","author":"Bhatt","year":"2017","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.ijcard.2021.08.031_bb0095","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ijcard.2004.05.009","article-title":"Low-density lipoprotein cholesterol estimation by a new formula in Indian population","volume":"102","author":"Anandaraja","year":"2005","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2021.08.031_bb0100","first-page":"478","article-title":"Determining a new formula for calculating low-density lipoprotein cholesterol: data mining approach","volume":"14","author":"Dansethakul","year":"2015","journal-title":"EXCLI J."},{"key":"10.1016\/j.ijcard.2021.08.031_bb0105","first-page":"339","article-title":"Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies","volume":"2","author":"Lawler","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2021.08.031_bb0110","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2019.4759","article-title":"Eligibility and preventive potential for new evidence-based cardiovascular drugs in secondary prevention","author":"Mortensen","year":"2020","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.ijcard.2021.08.031_bb0115","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1161\/CIRCULATIONAHA.118.038691","article-title":"Eligibility and cost for icosapent ethyl based on the REDUCE-IT trial","volume":"139","author":"Jia","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2021.08.031_bb0120","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/dom.13689","article-title":"Icosapent ethyl for dyslipidaemia in patients with diabetes and coronary artery disease: act now to reduce it","volume":"21","author":"Lan","year":"2019","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.ijcard.2021.08.031_bb0125","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"Laufs","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2021.08.031_bb0130","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jacl.2018.11.008","article-title":"Hypertriglyceridemia in statin-treated US adults: the National Health and nutrition examination survey","volume":"13","author":"Fan","year":"2019","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.ijcard.2021.08.031_bb0135","first-page":"1383","article-title":"Reduction in revascularization with icosapent ethyl: insights from REDUCE-IT REVASC","volume":"344","author":"Peterson","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2021.08.031_bb0140","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.008740","article-title":"High triglycerides are associated with increased cardiovascular events,\u00a0 medical costs, and resource use: a real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk","volume":"7","author":"Toth","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcard.2021.08.031_bb0145","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1016\/j.jacc.2017.03.585","article-title":"Trends in use of high-intensity statin therapy after myocardial infarction, 2011 to 2014","volume":"69","author":"Rosenson","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2021.08.031_bb0150","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1007\/s12325-021-01697-8","article-title":"Association of treatment intensity and adherence to lipid-lowering therapy with major adverse cardiovascular events among post-MI patients in Germany","volume":"38","author":"Ahrens","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ijcard.2021.08.031_bb0155","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijcard.2021.03.007","article-title":"Clinical impact and room for improvement of intensity and adherence to lipid lowering therapy: five years of clinical follow-up from 164,565 post-myocardial infarction patients","volume":"332","author":"Schiele","year":"2021","journal-title":"Int. J. Cardiol."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527321012973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527321012973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:53:45Z","timestamp":1759092825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527321012973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":31,"alternative-id":["S0167527321012973"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2021.08.031","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH) registry","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2021.08.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}